TARGET AUDIENCE
This educational activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows and other allied cancer professionals.

OVERVIEW OF ACTIVITY
Clinical controversies and uncertainties persist in the management of all common cancers, and thousands of ongoing research trials worldwide attempt to provide new answers to long-standing clinical questions. As these trials reach maturity, clinical investigators initially present new data in abridged format at large scientific conferences and subsequently in full data sets formally published as part of peer-reviewed journals. Today, numerous annual oncology conferences release new clinical data and hundreds of peer-reviewed publications feature articles related to cancer research, treatment and practical management. The extensive list of available treatment options poses a challenge to the practicing clinician who must maintain knowledge of appropriate clinical management strategies across a vast spectrum of liquid and solid tumors.

These proceedings from a daylong symposium combine the perspectives of 16 renowned investigators with a review of key recent presentations and publications across Hodgkin and non-Hodgkin lymphoma/chronic lymphocytic leukemia, breast cancer, genitourinary cancers, ovarian cancer, acute leukemias, lung cancer and gastrointestinal cancers to assist medical oncologists, hematologists, hematology-oncology fellows and other allied cancer professionals in the formulation of up-to-date clinical management strategies.

LEARNING OBJECTIVES

• Effectively apply the results of practice-changing clinical research to the care of patients with breast, lung, gastrointestinal, genitourinary, ovarian and select hematologic cancers.
• Appraise the clinical relevance of recent pivotal cancer research results published in peer-reviewed journals and/or presented at major oncology conferences.
• Recall ongoing trials in breast, lung, gastrointestinal, genitourinary, ovarian and select hematologic cancers, and refer appropriate patients for study participation.
• Use an understanding of tumor biomarkers and single and multigene signatures to individualize the care of patients with cancer.
• Educate patients with diverse hematologic cancers and solid tumors about the benefits and risks of new therapeutic agents and strategies.
• Refine or validate existing cancer-specific treatment algorithms based on exposure to new data sets and the perspectives of tumor-specific clinical investigators.
• Evaluate the mechanisms of action, tolerability and efficacy of promising investigational agents, and consider their potential implications for clinical practice.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
CME credit is no longer available for this issue

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
CME credit is no longer available for this issue

HOW TO USE THIS CME ACTIVITY
This CME activity consists of a video component.
CME credit is no longer available for this issue

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Jeremy Abramson, MD
Director of the Lymphoma Program
Jon and Jo Ann Hagler Chair in Lymphoma
Massachusetts General Hospital Cancer Center
Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Consulting Agreements: Celgene Corporation, Genentech BioOncology, Gilead Sciences Inc.

Deborah K Armstrong, MD
Director, Breast and Ovarian Surveillance Service
Professor of Oncology, Gynecology and Obstetrics
The Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, Maryland

Contracted Research: AstraZeneca Pharmaceuticals LP, Eisai Inc, Exelixis Inc, Pfizer Inc.

Jordan D Berlin, MD
Co-Leader, Gastrointestinal Cancer Research Program
Ingram Professor of Cancer Research
Professor of Medicine (Hematology/Oncology)
Director, Phase I Program
Vanderbilt University Medical Center
Nashville, Tennessee

Advisory Boards: AbbVie Inc, Aero Tech Labs, Beijing Pharmaceutical LTD, Celgene Corporation, EMD Serono Inc, Exelixis Inc, Five Prime Therapeutics Inc, Genentech BioOncology, Gritstone Oncology, Karyopharm Therapeutics, Rafael Pharmaceuticals Inc.

Michael Birrer, MD, PhD
Director, UAB Comprehensive Cancer Center
University of Alabama at Birmingham
Birmingham, Alabama

Advisory Committee: Roche Laboratories Inc.

Harry P Erba, MD, PhD
Albert F LoBuglio Endowed Chair for Translational Cancer Research
Chair, SWOG Leukemia Committee
Professor, Internal Medicine
Director, Hematologic Malignancy Program
University of Alabama at Birmingham
Birmingham, Alabama

Advisory Committee: Celgene Corporation, Novartis; Consulting Agreements: Amgen Inc, Celgene Corporation, Daiichi Sankyo Inc, Incyte Corporation, Jazz Pharmaceuticals Inc, MacroGenics Inc, Novartis, Ono Pharmaceutical Co Ltd, Pfizer Inc, Seattle Genetics, Sunesis Pharmaceuticals Inc; Contracted Research: Agios Pharmaceuticals Inc, Amgen Inc, Astellas Pharma Global Development Inc, Celator Pharmaceuticals Inc, Daiichi Sankyo Inc, ImmunoGen Inc, Janssen Biotech Inc, Juno Therapeutics, Seattle Genetics, Takeda Oncology; Data and Safety Monitoring Board and Chair: GlycoMimetics Inc; Speakers Bureau: Agios Pharmaceuticals Inc, Celgene Corporation, Incyte Corporation, Jazz Pharmaceuticals Inc, Novartis.

Axel Grothey, MD
Professor of Oncology
Department of Medical Oncology
Mayo Clinic
Rochester, Minnesota

Advisory Committee: Amgen Inc, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Genentech BioOncology, Roche Laboratories Inc; Contracted Research: Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Eisai Inc, Genentech BioOncology.

Hagop M Kantarjian, MD
Chairman and Professor, Leukemia Department
The University of Texas MD Anderson Cancer Center
Houston, Texas

No relevant conflicts of interest to disclose.

Ann S LaCasce, MD, MMSc
Program Director, Fellowship in Hematology/Oncology
Associate Professor of Medicine, Harvard Medical School
Lymphoma Program
Dana-Farber Cancer Institute
Boston, Massachusetts

Advisory Committee: Bristol-Myers Squibb Company, Forty Seven Inc; Consulting Agreement: Seattle Genetics.

William K Oh, MD
Chief, Division of Hematology and Medical Oncology
Professor of Medicine and Urology
Ezra M Greenspan, MD Professor in Clinical Cancer Therapeutics
Icahn School of Medicine at Mount Sinai
Associate Director of Clinical Research
The Tisch Cancer Institute
Mount Sinai Health System
New York, New York

Advisory Committee: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Churchill Pharmaceuticals, Dendreon Pharmaceuticals Inc, Janssen Biotech Inc, Sanofi Genzyme.

Joyce O’Shaughnessy, MD
Chair, Breast Cancer Research Program
Baylor Charles A Sammons Cancer Center
Celebrating Women Chair in Breast Cancer Research
Texas Oncology
US Oncology
Dallas, Texas

Advisory Committee and Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Eisai Inc, Genentech BioOncology, Lilly, Merck, Novartis, Pfizer Inc, Roche Laboratories Inc, Sanofi Genzyme, Takeda Oncology; Contracted Research: Merck.

Daniel P Petrylak, MD
Professor of Medicine
Director, Prostate and GU Medical Oncology
Co-Director, Signal Transduction Program
Yale Cancer Center
New Haven, Connecticut

Consulting Agreements: Bayer HealthCare Pharmaceuticals, Bellicum Pharmaceuticals Inc, Dendreon Pharmaceuticals Inc, Exelixis Inc, Ferring Pharmaceuticals, Johnson & Johnson Pharmaceuticals, Medivation Inc, a Pfizer Company, Pfizer Inc, Roche Laboratories Inc, Sanofi Genzyme, Takeda Oncology, Tyme Technologies Inc; Contracted Research: Agensys Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Dendreon Pharmaceuticals Inc, Endocyte Inc, Genentech BioOncology, Innocrin Pharmaceuticals Inc, Johnson & Johnson Pharmaceuticals, Lilly, MedImmune Inc, Medivation Inc, a Pfizer Company, Merck, Novartis, OncoGenex Pharmaceuticals Inc, Pfizer Inc, Progenics Pharmaceuticals Inc, Roche Laboratories Inc, Sanofi Genzyme, SOTIO LLC, Takeda Oncology; Ownership Interest: Bellicum Pharmaceuticals Inc, Tyme Technologies Inc.

Gregory J Riely, MD, PhD
Associate Attending
Memorial Sloan Kettering Cancer Center
New York, New York

Contracted Research: Genentech BioOncology, Pfizer Inc, Takeda Oncology; Paid Travel: Merck; Other: AstraZeneca Pharmaceuticals LP.

Hope S Rugo, MD
Professor of Medicine
Director, Breast Oncology and Clinical Trials Education
University of California, San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, California

Contracted Research: Amgen Inc, Eisai Inc, Genentech BioOncology, GlaxoSmithKline, Lilly, MacroGenics Inc, Merck, Novartis, OBI Pharma Inc, Pfizer Inc, Roche Laboratories Inc.

Sonali M Smith, MD
Associate Professor
Section of Hematology/Oncology
Director, Lymphoma Program
The University of Chicago
Chicago, Illinois

Consulting Agreements: Bristol-Myers Squibb Company, Celgene Corporation, Gilead Sciences Inc, Juno Therapeutics, Pharmacyclics LLC, an AbbVie Company, TG Therapeutics Inc.

David R Spigel, MD
Program Director, Lung Cancer Research
Sarah Cannon Research Institute
Nashville, Tennessee

No relevant conflicts of interest to disclose

Heather Wakelee, MD
Associate Professor of Medicine
Division of Oncology
Stanford University School of Medicine
Stanford Cancer Institute
Stanford, California

Consulting Agreements: ACEA Biosciences Inc, Genentech BioOncology, Helsinn Group, Peregrine Pharmaceuticals Inc, Pfizer Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Exelixis Inc, Genentech BioOncology, Gilead Sciences Inc, Lilly, MedImmune Inc, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc, Xcovery; Honoraria: ACEA Biosciences Inc, Helsinn Group, Peregrine Pharmaceuticals Inc.

MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from AbbVie Inc, Agios Pharmaceuticals Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Eisai Inc, Exelixis Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, ImmunoGen Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Lexicon Pharmaceuticals Inc, Lilly, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Sanofi Genzyme, Seattle Genetics, Taiho Oncology Inc, Takeda Oncology and Tesaro Inc.

Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
Adobe Flash Player 27 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Last review date: January 2018
Expiration date: January 2019